Search - tctmd.com

Displaying 41 - 50 of 50

Sort: Relevancy | Date

News Features

Top News in Clinical Cardiology: 2018

Yael L. Maxwell

December 28, 2018

News Features

Top News in Prevention: 2018

Michael O'Riordan

December 28, 2018

News Daily News

European Regulators Strike Secondary Prevention Claim for Omega-3 Drugs

Shelley Wood

December 18, 2018

News Conference News AHA 2018

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

Todd Neale

November 10, 2018

News Daily News

Prescription Omega-3 Fatty Acids Cut Cardiovascular Events: REDUCE-IT

Shelley Wood

September 24, 2018

News Daily News

¿Relaja el Acuerdo de la FDA con Amarin el Control de las Promociones Fuera de Indicación?

Michael O'Riordan

March 09, 2016

News Daily News

Will FDA’s Settlement With Amarin Weaken Agency Oversight of Off-Label Promotion?

Michael O'Riordan

March 09, 2016

News Daily News

FDA 与阿玛琳之间的和解是否会减弱该局对标签外用途推广的监督？

Michael O'Riordan

March 09, 2016

News Industry News

Amarin Reaffirms Its Mission to Improve Patient Care With Commitment to Completing REDUCE-IT Cardiovascular Outcomes Study

September 16, 2014

News Industry News

Amarin Announces Publication of Case Study Results Describing Reductions in Multiple Lipid Parameters for Individual Hyperlipidemic Patients Switched to Vascepa(R)

June 11, 2014

Advertisement

Top News in Clinical Cardiology: 2018

Top News in Prevention: 2018

European Regulators Strike Secondary Prevention Claim for Omega-3 Drugs

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

Prescription Omega-3 Fatty Acids Cut Cardiovascular Events: REDUCE-IT

¿Relaja el Acuerdo de la FDA con Amarin el Control de las Promociones Fuera de Indicación?

Will FDA’s Settlement With Amarin Weaken Agency Oversight of Off-Label Promotion?

FDA 与阿玛琳之间的和解是否会减弱该局对标签外用途推广的监督？

Amarin Reaffirms Its Mission to Improve Patient Care With Commitment to Completing REDUCE-IT Cardiovascular Outcomes Study

Amarin Announces Publication of Case Study Results Describing Reductions in Multiple Lipid Parameters for Individual Hyperlipidemic Patients Switched to Vascepa(R)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content